Mark Erlander, Cardiff Oncology CEO

Cardiff teas­es on­va­nsert­ib ef­fi­ca­cy in col­orec­tal can­cer ahead of first-line read­out

Cardiff On­col­o­gy’s PLK1 in­hibitor showed hints of ef­fi­ca­cy in a shelved Phase II test in sec­ond-line col­orec­tal can­cer, boost­ing Cardiff’s share price ahead of an up­com­ing read­out in the front­line set­ting.

The de­pri­or­i­tized ON­SEM­BLE tri­al stud­ied two dos­es of the drug can­di­date, on­va­nsert­ib, plus stan­dard of care FOLFIRI and Genen­tech’s Avastin ver­sus stan­dard of care in metasta­t­ic col­orec­tal can­cer (mCRC) pa­tients with a KRAS or NRAS mu­ta­tion who had re­ceived one pri­or chemother­a­py-based treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.